---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-031379"
form_type: "8-K"
ticker: "PVCT"
cik: "0000315545"
company_name: "PROVECTUS BIOPHARMACEUTICALS, INC."
filed_at: "2026-06-30T23:37:26+00:00"
generated_at: "2026-07-01T10:05:47.916639+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Provectus Biopharmaceuticals converts $542,500 in accrued director fees into Series D-1 Preferred Stock

## Summary
- Board approved conversion of $542,500 in accrued directors' fees into 189,554 shares of Series D-1 Preferred Stock.
- Preferred Stock is convertible into 1,895,540 shares of Common Stock.
- Issuance satisfies outstanding cash fees, not under 2024 Equity Compensation Plan.
- Conversion effective as of June 30, 2026, based on May 14, 2026 Board approval.

## SEC filing metadata
- accession: 0001493152-26-031379
- form_type: 8-K
- ticker: PVCT
- cik: 0000315545
- company_name: PROVECTUS BIOPHARMACEUTICALS, INC.
- filed_at: 2026-06-30T23:37:26+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/315545/000149315226031379/0001493152-26-031379-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/315545/000149315226031379/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-031379
- JSON: https://secwatch.observer/filing/0001493152-26-031379.json
- Plain text: https://secwatch.observer/filing/0001493152-26-031379.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.